NCT05917912View on ClinicalTrials.gov

EASE (Efficacy of ATX01 Study in Erythromelalgia)

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Erythromelalgia
Interventions
DRUG

Amitriptyline Hydrochloride

hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks

DRUG

Placebo

hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks

Trial Locations (2)

55905

Mayo Clinic, Rochester

Unknown

Universitätsklinikum Erlangen Hautklinik, Erlangen

Sponsors

Lead Sponsor

AlgoTherapeutix
All Listed Sponsors
lead

AlgoTherapeutix

INDUSTRY

NCT05917912 - EASE (Efficacy of ATX01 Study in Erythromelalgia) | Biotech Hunter | Biotech Hunter